



DZ/Y


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 7/08, C07D 209/04		A1	(11) International Publication Number: WO 98/06725
			(43) International Publication Date: 19 February 1998 (19.02.98)
(21) International Application Number: PCT/US97/13799		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 August 1997 (08.08.97)			
(30) Priority Data: 60/023,860 13 August 1996 (13.08.96) US 9619064.0 12 September 1996 (12.09.96) GB 60/030,155 31 October 1996 (31.10.96) US			
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): CHEN, Cheng-Yi [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LARSEN, Robert, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			

(54) Title: PALLADIUM CATALYZED INDOLIZATION

(57) Abstract

We have found that 2-unsubstituted indoles of structural formula (IV) can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy aniline (I) and an acyl silane derivative (II), followed by deprotection of the silyl protecting groups. The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride. When applied to 5-triazolyl substituted indoles, the present process also eliminates the tendency of triazolyl polymerization in the Fischer indole synthesis. Still further, the present invention is also directed to the novel intermediates of structural formulae (V) and (VI).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Kazakhstan	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

TITLE OF THE INVENTION

PALLADIUM CATALYZED INDOLIZATION


BACKGROUND OF THE INVENTION

5 The present invention relates to the preparation of 2-silyl protected indoles from the palladium catalyzed reaction of halo-anilines and acyl silanes (which act as aldehyde synthons). These 2-silyl derivatives may, according to the present invention, be converted to the corresponding 2-unsubstituted indole derivative. The present invention
10 is particularly useful in the preparation of 5-heterocyclic substituted tryptamines such as 5-(1,2,4-triazol-1-yl) tryptamine. These compounds are therapeutically active as anti-migraine agents.

 Generally, indoles are prepared via the Fischer-indole reaction. For example, Chen *et al.*, *J. Org. Chem.*, 59:3738 (1994)
15 disclose the preparation of N,N-dimethyl tryptamines from 4-substituted hydrazines and dimethylaminobutyraldehyde dimethyl acetal using 4% H₂SO₄. However, the yields are often low, particularly for compounds having triazole substitution. Benzyltriazoles are unstable to the Fischer indole reaction conditions, which generally lead to polymerization of the
20 triazole moiety, and the production of oligomers.

 Larock *et al.*, *J. Am. Chem. Soc.*, 113:6689 (1991) have shown that coupling of an iodoaniline species with an internal acetylene using palladium catalysis gives 2,3-disubstituted indoles in good-to-excellent yields. Smith *et al.*, have also demonstrated this for 4-
25 pyrimidinyl and pyridinyl derivatives of indol-3-yl-alkyl piperazines as in published EPO 548 831 A1. Two other applications of this methodology have been demonstrated in the syntheses of hetero-condensed pyrroles and tryptophans. See Wensbo *et al.*, *Tetrahedron Lett.*, 34:2823 (1993); Wensbo *et al.*, *Tetrahedron Lett.*, 34:6471
30 (1993). However, all of these methods require triphenylphosphine, as part of the catalyst system, which is an environmental hazard. An alternate process has been developed to overcome the low yield of the Fischer-indole reaction with certain starting materials and to avoid the use of the environmentally hazardous triphenylphosphine. This process

is detailed in PCT publication WO 95/32197 and involves the palladium-catalyzed coupling/ring closure of a 3-iodo-4-aminobenzyltriazole with a suitably protected butynol derivative to the corresponding tryptophol, followed by conversion of the hydroxyethyl moiety to a dimethyl amino ethyl; as shown below:



said process being carried out in a dry inert organic solvent for the starting materials at a temperature in the range of about 70 to 120°C, in the presence of a palladium catalyst, and in the presence of an inorganic or organic amine compound, wherein:

- X₂₁ and X₂₂ are independently ring nitrogen or carbon atoms;
- halo represents Br or I;
- n is an integer from 0-1;
- p is an integer from 1-4;
- R²³ is H or linear or branched C₁-C₄ alkyl;

R²¹ is H or a radical with functions as a hydroxy protecting group, which is removable, under mild acid hydrolyses, for example, by contacting with a mixture of HCl/MeOH, e.g. 1:1 2N HCl/MeOH at 0-30°C, and


5 R²² is a radical which functions as a terminal acetylene carbon protecting group.

However, although the chemistry of this alternate process is effective, the starting materials, butynol and triethylsilyl chloride, are relatively expensive. The present invention provides for a cost-effective
10 indolization procedure.

Iida et al., J. Org. Chem. 45:2938-2942 (1980) describe intramolecular cyclization of 3-((2-bromoaryl)amino) cyclohex-2-en-1-ones with catalytic palladium in the presence of triphenyl phosphine, as well as the reaction of aryl amines with β -diketones to form the
15 corresponding secondary enaminone followed by N-ethylation to form the corresponding tertiary enaminones and subsequent intramolecular cyclization in the presence of equimolar palladium acetate.

Sakamota et al., Synthesis, p. 215-218 (1990), describe palladium-catalyzed cyclization of β -(2-halophenyl)amino substituted
20 α,β -unsaturated ketones and esters to produce 2,3-disubstituted indoles. The procedure of Sakamota et al., also employs phosphine.

The present invention has particular application in the synthesis of 5HT_{1D} receptor agonists. These agonists mimic the effects of the neurotransmitter serotonin which acts as a vasoconstrictor in the
25 brain. 5HT_{1D} receptor agonists display beneficial properties in migraine therapies. Over the past few years an extensive effort has been devoted to the development of *N,N*-dialkyltryptamines as 5-HT_{1D} receptor agonists to achieve the desired activity and selectivity for the treatment of migraine. Sumatriptan is the first of this class of drugs to
30 be approved for this purpose. MK-0462 (developed by Merck & Co.), is described in U.S. 5,298,520 and is also a potent 5-HT_{1D} receptor agonist that is undergoing clinical studies.




Thus, the present invention also provides for an efficient and cost-effective synthesis of 5-heterocyclic-substituted tryptamines useful in the treatment of migraine headaches.

SUMMARY OF THE INVENTION

We have found that 2-unsubstituted indoles can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy (OTf)- aniline and an acyl silane derivative, followed by deprotection of the silyl protecting groups. The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages to the present process are that it does not require the use of triphenylphosphine or tetrabutyl ammonium chloride or lithium chloride. When applied to 5-triazolyl substituted indoles, the present process also eliminates the tendency of triazolyl polymerization in the Fischer indole synthesis.

By this invention, there is provided a process comprising the step of contacting a compound of Structure I with a compound of Structure II to form a compound of Structure III:



wherein Y is selected from Br, I, and triflate, and R^1 , R^2 , R^3 , R^4 , and R^8 are each substituents that will not interfere with the reaction conditions, and R^5 , R^6 , and R^7 each represent C_{1-6} alkyl, OC_{1-6} alkyl, or phenyl.

More particularly, the present invention relates to the reaction above wherein:

Y is selected from Br, I and triflate;

R^1 , R^2 , R^3 and R^4 are each independently selected from:

(1) hydrogen;


(2) $(CH_2)_n - N \begin{array}{c} X^1-X^2 \\ | \\ =N \\ | \\ R^9 \end{array}$;

(3) C₁-6 alkyl;


(4) -(CH₂)_n-Z

wherein Z represents:


- 5
- (a) hydrogen,
- (b) halogen,
- (c) cyano,
- (d) nitro,
- (e) trifluoromethyl,
- 10 (f) -OR¹⁰,
- (g) -OCOR¹⁰,
- (h) -OCONR¹⁰R¹¹,
- (i) -OCH₂CN,
- (j) -OCH₂CONR¹⁰R¹¹,
- 15 (k) -SR¹⁰, provided that R¹⁰ is not hydrogen,
- (l) -SOR¹⁰,
- (m) -SO₂R¹⁰,
- (n) -SO₂NR¹⁰R¹¹,
- (o) -NR¹⁰R¹¹,
- 20 (p) -NR¹⁰COR¹¹,
- (q) -NR¹⁰CO₂R¹¹,
- (r) -NR¹⁰SO₂R¹¹,
- (s) -COR¹⁰,
- (t) -CO₂R¹⁰,
- 25 (u) -CONR¹⁰R¹¹,
- or Z is a group of formula (Za), (Zb), (Zc), or (Zd):




(Za)



(Zb)



(Zc)



(Zd)

or Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole;

R⁵, R⁶, and R⁷ are each independently selected from:

- (1) C₁₋₆ alkyl,
- (2) -O-C₁₋₆ alkyl, and
- (3) phenyl;

R⁸ is selected from:

- (1) hydrogen,
- (2) -R¹⁹-OH,
- (3) -R¹⁹-O-R¹⁷, and
- (4) -R¹⁹NR¹²R¹³, and
- (5) -R¹⁹-Z¹

wherein: Z¹ is a 3 to 7 membered heterocyclic ring wherein the ring members are selected from 1 to 2 nitrogen atoms and wherein the heterocyclic ring may be substituted by one or more R¹⁴;

R⁹ is selected from:

- (1) hydrogen, and
- (2) C₁₋₄ alkyl;

R¹⁰ and R¹¹ are each independently selected from:

- (1) hydrogen,
- (2) C₁₋₆ alkyl,
- (3) trifluoromethyl,
- (4) phenyl, optionally substituted with one or more R²⁰ substituents
- (5) methylphenyl, optionally substituted with one or more R²⁰ substituents, and

- (6) an arylC₁-6alkyl- or heteroaryl C₁-6alkyl- group, optionally substituted with one or more R²⁰ substituents, or

R¹⁰ and R¹¹ when linked through a nitrogen atom, together represent the residue of an optionally substituted azetidine, pyrrolidine, piperidine, morpholine or piperazine ring, optionally substituted with one or more R¹⁸ substituents;

R¹² and R¹³ are each independently selected from:

- (1) C₁-4 alkyl,
- (2) C₆aryl-C₁-4 alkyl- wherein aryl may be unsubstituted or substituted with one to three substituents selected from methyl, halo, and halomethyl,

R¹⁴ is selected from:

- (1) aryl-C₁-6alkyl-, unsubstituted or substituted with one to three R²⁰ substituents, and
- (2) heteroaryl-C₁-6alkyl-, unsubstituted or substituted with one to three R²⁰ substituents,

R¹⁵ and R¹⁶ are each independently selected from

- (1) hydrogen,
- (2) C₁-6alkyl,
- (3) C₃-7cycloalkyl,
- (4) C₃-7cycloalkylC₁-6alkyl-,
- (5) indanyl,
- (6) aryl,
- (7) arylC₁-6alkyl-,
- (8) C₃-7heterocycloalkyl-,
- (9) C₃-7heterocycloalkylC₁-6alkyl-,
- (10) heteroaryl, and
- (11) heteroarylC₁-6alkyl-;

R¹⁷ is selected from a hydroxy protecting group that is removable under mild acid hydrolysis;


R¹⁸ is selected from:

- 5
- (1) C₁-6alkyl-,
 - (2) arylC₁-6alkyl-,
 - (3) C₁-6alkoxy-,
 - (4) C₂-6alkyoxycarbonyl-, and
 - (5) C₁-6alkylaminocarbonyl-;

R¹⁹ is a straight or branched C₁-6alkyl chain;

R²⁰ is selected from:

- 10
- (1) fluoro,
 - (2) cyano,
 - (3) trifluoromethyl,
 - (4) C₁-6alkyl,
 - (5) haloC₁-6alkyl-,
 - (6) aryl,
 - (7) triazolyl,
 - 15 (8) tetrazolyl,
 - (9) tetrazolyl-C₁-6alkyl-,
 - (10) hydroxy,
 - (11) C₁-6alkoxy-,
 - (12) C₁-6alkylthio-,
 - 20 (13) C₂-6alkoxycarbonyl-,
 - (14) C₂-6alkylcarbonyl-,
 - (15) C₁-6alkylsulphonyl-,
 - (16) arylsulfonyl-,
 - (17) C₂-6alkylcarbonylamino-,
 - 25 (18) arylcarbonylamino-,
 - (19) C₂-6alkoxycarbonylamino-,
 - (20) N-C₁-6alkyl-N-C₂-6alkoxyamino-,
 - (21) carbonylamino-,
 - (22) mono- or diarylamino-
 - 30 (23) pyrrolidinylcarbonylamino-,
 - (24) piperidinylcarbonylamino-,
 - (25) aminocarbonyl-,
 - (26) aminocarbonylamino-,

- (27) C₁-6alkylaminocarbonyl-,
 (28) C₁-6alkylaminocarbonylamino-,
 (29) diC₁-6alkylaminocarbonyl-,
 (30) diC₁-6alkylaminocarbonylamino-,
 5 (31) pyrrolidinylcarbonylamino-,
 (32) piperidinylcarbonylamino-,
 (33) aminosulfonyl-,
 (34) C₁-6alkylaminosulfonyl-,
 (35) C₁-6alkylsulfonylamino-,
 10 (36) C₁-6alkylsulfonylaminomethyl-,
 (37) arylsulfonylamino-,
 (38) diC₁-6alkylaminosulfonyl-,
 (39) aminosulphonylmethyl-,
 15 (40) C₁-6alkylaminosulphonylmethyl-,
 (41) diC₁-6alkylaminosulphonylmethyl-,
 (42) -(CH₂)_mOR¹⁵,
 (43) -(CH₂)_mSR¹⁵, provided that R¹⁵ is not hydrogen,
 (44) -(CH₂)_mSOR¹⁵,
 (45) -(CH₂)_mSO₂R¹⁵,
 20 (46) -(CH₂)_mNR¹⁵R¹⁶,
 (47) =O, and
 (48)  ;

- 25 X¹ and X² are each independently selected from ring nitrogen or
 ring carbon atoms;
 X³ is selected from the group consisting of oxygen, sulfur, -NH-
 or methylene;
 Y¹ is oxygen or sulfur;
 30 n is an integer independently selected at each occurrence from 0
 and 1;


m is an integer selected independently at each occurrence from 0 to 4; and

p is an integer from 0 to 3.

The process is preferably carried out in a dry organic solvent inert for the starting materials at a temperature range of 90 to 120°C in the presence of a palladium catalyst, and in the presence of a proton acceptor which may be an inorganic or organic amine compound.


Where Z in the compounds of formulae I and III above represents a five-membered heteroaromatic ring, this ring may be optionally substituted by one or, where possible, two substituents. As will be appreciated, where Z represents oxadiazole, thiadiazole or tetrazole ring, only one substituent will be possible; otherwise, one or two optional substituents may be accommodated around the five-membered heteroaromatic ring Z. Examples of suitable substituents on the five-membered heteroaromatic ring Z include C₁-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl, C₃-7 cycloalkyl, aryl, aryl C₁-6 alkyl, C₃-7 heterocycloalkyl, heteroaryl, C₁-6 alkoxy, C₁-6 alkylthio, amino, C₁-6 alkylamino, diC₁-6 alkylamino, halogen, cyano, and trifluoromethyl.

Further, the present invention relates to deprotecting the compound of structural formula III to obtain the 2-unsubstituted indole of structural formula IV:



wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are as defined above.

Still further, the present invention is also directed to the novel intermediates of structural formulae (V) and (VI).



DETAILED DESCRIPTION OF THE INVENTION

Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

In one embodiment of the present invention, R^1 , R^3 , and R^4 are each hydrogen and R^2 , R^5 , R^6 , R^7 , R^8 , and Y are as defined above.

Representative examples of $\text{Si}(\text{R}^5)(\text{R}^6)(\text{R}^7)$ radicals include trimethyl silyl, triethyl silyl, tributyl silyl, triphenyl silyl, dimethyl-*t*-butyl silyl, dimethylphenyl silyl, diphenylmethyl silyl, triisopropyl silyl, and the like, as well as any mixture of $-\text{Si}(\text{OC}_{1-6} \text{ alkyl})_3-n(\text{C}_{1-6} \text{ alkyl})_n$, where n is 0, 1, or 2.

R^{17} acts as a protecting group for the hydroxyl group and may have the structure $\text{Si}(\text{R}^5)(\text{R}^6)(\text{R}^7)$, as described above.

The term "triflate" or "OTf" refers to the trifluoromethane sulfonyloxy group.

When an amine is included as a substituent on a compound in the present invention, in order to optimize the conditions of the reaction and to obtain better yields, the amine may have to be protected, as is known in the art, and the protecting group removed following the coupling reaction.

When a carbonyl group is included as a substituent on a compound in the present invention, in order to optimize the conditions of the reaction and to obtain better yields, the carbonyl group may have to be protected, as is known in the art, and the protecting group removed following the coupling reaction.

When an alkenyl or alkynyl group is included as a substituent on a compound in the present invention, in order to optimize the conditions of the reaction and obtain better yields, the alkenyl or alkynyl group may be protected by conversion to an oxide, followed by
5 reduction. Alternatively, an additional elimination strategy may be employed.

As used herein "alkyl", particularly the expression "C₁₋₆ alkyl", includes methyl and ethyl groups and straight chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl
10 groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as C₁₋₆alkoxy, C₁₋₆alkylthio, and C₁₋₆alkyl amino are to be construed accordingly.

The expression "C₂₋₆alkenyl" as used herein refers to straight chained and branched alkenyl groups containing from 2 to 6
15 carbon atoms. Typical examples include vinyl, allyl, dimethylallyl and butenyl groups.

The expression "C₂₋₆alkynyl" as used herein refers to straight-chained and branched alkynyl groups containing from 2 to 6
20 carbon atoms. Typical examples include ethynyl and propargyl groups.

Typical C₃₋₇cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

Typical aryl groups include phenyl and naphthyl. More particularly, aryl is phenyl.

Particular indanyl groups include indan-1-yl and indan-2-
25 yl.

Particular arylC₁₋₆alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

Suitable heterocycloalkyl groups include azetidiny, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl.
30

Suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,

imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, and tetrazolyl groups.

The expression "heteroaryl C₁-6alkyl" as used herein includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, 5 oxazolymethyl, oxazolylethyl, thiazolymethyl, thiazolylethyl, imidazolymethyl, imidazolylethyl, oxadiazolymethyl, oxadiazolylethyl, thiadiazolymethyl, thiadiazolylethyl, triazolymethyl, triazolylethyl, tetrazolymethyl, tetrazolylethyl, pyridylmethyl, pyridylethyl, pyridinylmethyl, pyrazinylmethyl, quinolylmethyl, and 10 isoquinolylmethyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine, unless otherwise specified.

The process of the present invention is preferably carried 15 out in a dry organic solvent inert for the starting materials in the presence of a palladium catalyst, and in the presence of an inorganic or organic base which is not a "catalyst poison". Preferably, the present process is carried out at an elevated temperature.

In the process of the present invention, Structure I is 20 coupled with Structure II to form Structure III via a palladium catalyzed reaction in a dry inert organic solvent containing a soluble palladium catalyst and in the presence of a proton acceptor, being an aromatic amine, alkylamine or inorganic base, which is not a "catalyst poison," at a temperature of about 90-120°C.

The organic solvent useful in the process of the present 25 invention must be one in which Structure I, Structure II and the palladium catalyst are soluble and compatible and is chemically inert under the reaction conditions. Preferred are DMSO (dimethylsulfoxide) and amide solvents such as DMF (N,N-dimethylformamide), DMAC (N,N-dimethylacetamide), and NMP (N-methyl-pyrrolidinone). Most 30 preferred is DMF.

The acyl silane of structural formula (II) is generally employed in excess based on the the 2-halo or 2-(OTf)- aniline of structural formula (I). A useful range is about 1.0 to 3 fold, based on

the 2-halo or 2-(OTf)- aniline of structural formula I. The acyl silane may be favorably employed at a two-fold excess, based on the 2-halo or 2-(OTf)- aniline of structural formula I.

5 The proton acceptor useful in the process of the present invention is a basic compound which can be organic or inorganic and acts as a proton acceptor and is not a "catalyst poison". By the term "catalyst poison" is meant interaction with the catalyst to inhibit its catalytic activity and prevent the coupling/ring closure between structures I and II from occurring. Suitable classes of proton acceptors
10 include alkylamines, aromatic amines, heterocyclic amines, phosphates and the like.

Alkylamines are the preferred proton acceptor in the process of the present invention. Particular alkylamines that may be employed include: DABCO (1,4-diazabicyclo[2.2.2]octane), quinuclidine, t-
15 butylamine, 2,2,6,6,-tetramethylpiperidine and di-t-butyl-amine. DABCO is particularly preferred because it reduces the appearance of impurities in the reaction because it is resistant to oxidation to the imine in the reaction conditions of the process of the present invention.

The proton acceptor is generally employed in excess based
20 on the the 2-halo or 2-(OTf)- aniline of structural formula (I). A useful range is about 2 to 4 fold excess, based on the 2-halo or 2-(OTf)- aniline of structural formula (I). The proton acceptor may be favorably employed at a three-fold excess, based on the 2-halo or 2-(OTf)- aniline of structural formula (I).

25 The palladium catalyst useful in the reaction can be selected from the following classes: Pd alkanoates, Pd acetonates, Pd halides, Pd halide complexes, Pd-benzylidene acetone complexes; as well as triaryl Pd phosphine complexes. Representative examples include, but are not limited to: Pd(II) acetate, Pd(II) acetylacetonate, Pd(O)bis-
30 dibenzylidene acetone ("dba"), Pd(II) bromide, Pd(II) chloride, Pd(II) iodide, Pd(II) sulfate, Pd(II)trifluoroacetate, Pd(II) Cl₂(CH₃CN)₂, Pd₂(dba)₃, and Pd(II)Cl₂(PhCN)₂. A useful catalyst is palladium acetate.

The palladium catalyst is employed in an amount of about 0.5 to 5 mole percent based on the halo aniline of structural formula I.


A useful range is about 2 to 3 mole percent of soluble palladium catalyst, based on the halo aniline of structural formula I.

5 A dehydrating agent, such as magnesium sulfate may also be favorably employed in the process of coupling Structure I with Structure II to form Structure III according to the present invention. Although not necessary to the process, a dehydrating agent can assist the enamine formation by removal of the water of condensation.

10 The reaction is carried out in the temperature range of 90 to 120°C. A useful temperature is about 100-105°C. Generally, the reaction is carried out under a dry, inert atmosphere at atmospheric pressure. It is useful to carry out the reaction under a nitrogen atmosphere.

15 The progress of the reaction may be monitored by means known in the art, including thin-layer silica gel chromatography (TLC), high pressure liquid chromatography (HPLC), gas chromatography (GC), and nuclear magnetic resonance spectroscopy (NMR). Preferably HPLC or TLC is employed, most preferably HPLC. When the reaction is complete, generally in 8 to 72 hours, the reaction mixture is cooled to room temperature and the product is separated by traditional means, 20 e.g. by taking up with organic solvent, such as isopropyl acetate and washing with water and/or other aqueous solutions. The product may then be purified by means known in the art, including preparative thin-layer silica gel chromatography, silica gel chromatography, HPLC, crystallization, and solid-phase extraction. Preferably, the product is 25 purified by silica gel chromatography or crystallization.

Further, the present invention relates to deprotecting the compound of structural formula III to obtain the 2-unsubstituted indole of structural formula IV:



wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are as defined above.

The Si(R⁵)(R⁶)(R⁷) group is removable by Lewis acid catalyzed deprotection with a Lewis acid such as AlCl₃, or aqueous HCl
 5 HF, HBr, and HI. The silyl group may be removed, for example, by treatment with nucleophilic acid, e.g., contacting with about a 1:1 by volume 2N HCl/MeOH solvent mixture at 0-30°C for 1 to 24 hours to completely remove the silyl protecting groups. Alternatively, the silyl group may be removed by fluoride deprotection. This step is referred to herein as "deprotection". Removal of the Si(R⁵)(R⁶)(R⁷) group
 10 produces the 2-unsubstituted indole.

Particular 2-unsubstituted indole compounds according to structural formula (IV) that may be made according to the process of the present invention include:

- 15 (1) 1-benzyl-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazin-2-one;
- (2) 1-(2-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazin-2-one;
- (3) 1-[2-(3-fluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazin-2-one;
- 20 (4) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(*N*-methyl)aminosulphonylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (5) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(aminosulphonylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 25 (6) (3*S*)-3-(*N*-benzyl)aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- (7) (3*S*)-3-[*N*-(*R*)- α -(hydroxymethyl)benzyl]aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 5 (8) (3*S*)-3-[*N*-(*S*)- α -methylbenzyl]aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (9) 4-[*N*-(*R*)- α -(hydroxymethyl)benzyl]amino-(*S*)-1-[3-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (10) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-(*S*)-1-[2-(5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (11) (3*R*)-3-[*N*-(*S*)- α -methylbenzyl-*N*-methyl]aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 15 (12) (3*R*)-3-[*N*-(*S*)- α -methylbenzyl-*N*-methyl]aminomethyl-(*S*)-1-[2-(5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (13) (3*S*)-3-[*N*-(4-fluorobenzyl)-*N*-methyl]aminomethyl-(*S*)-1-[2-(5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 20 (14) 4-benzyl-12-(2-fluoromethyl-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl)piperazine;
- (15) 4-[2-(3-fluorophenyl)ethyl]-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 25 (16) 4-benzyl-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (17) 4-(*N*-benzyl-*N*-methylamino)-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 30 (18) 4-[(*R*)-2-hydroxy-1-(4-fluorophenyl)ethylamino]-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (19) 7-benzyl-2-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;

- (20) 7-(3-furylmethyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (21) 7-(2-phenylethyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- 5 (22) 7-(4-fluorobenzyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (23) 7-(2,4-difluorobenzyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (24) 4-(2,2-difluoro-1-oxo-2-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- 10 (25) 4-benzyl-3-methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- (26) 4-benzyl-3-methoxymethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 15 (27) 1-(2-hydroxy-1-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (28) 1-[2-(2-fluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (29) 1-benzyl-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- 20 (30) 1-(3,3-dimethylbutyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (31) 1-(2-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- 25 (32) 1-cyclohexylmethyl-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (33) 1-(3-phenylpropyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (34) 1-[2-(3-fluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- 30 (35) 1-[2-(4-trifluoromethylphenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (36) 1-[2-(3,4-difluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;

- (37) *N*-methyl-2-phenyl-2-[4-(3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl)piperidin-1-yl]acetamide;
- (38) 1-(2-oxo-2-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 5 (39) 1-(2-phenylpropyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (40) 4-benzyl-4-fluoro-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (41) 4-fluoro-4-[2-(3-fluorophenyl)ethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (42) 4-fluoro-4-(3-fluorobenzyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (43) 4-fluoro-4-(2-fluorobenzyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 15 (44) 4-benzyl-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (45) 4-benzyl-4-methoxy-1-[3-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)propyl]piperidine;
- (46) 4-(2-fluorobenzyl)-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 20 (47) 4-(3-fluorobenzyl)-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (48) 4-(4-fluorobenzyl)-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 25 (49) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(oxazol-2-on-3-yl)-1-phenylethyl]piperazine;
- (50) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(oxazolidin-2-on-3-yl)-1-phenylethyl]piperazine;
- (51) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-(oxazolidin-2-on-3-yl)ethyl]piperazine;
- 30 (52) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-hydroxy-1-phenylpropyl)piperazine;
- (53) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(imidazol-1-yl)-1-phenylethyl]piperazine;

- 5 (54) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-hydroxyethyl]piperazine;
(55) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-methoxyethyl]piperazine;
(56) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-phenylpropyl]piperazine;
(57) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-benzyloxy-1-(4-fluorophenyl)ethyl]piperazine;
10 (58) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-methoxypropyl]piperazine;
(59) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-(imidazol-1-yl)ethyl]piperazine;
(60) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-phenyl-2-(pyrrolidin-1-yl)ethyl]piperazine;
15 (61) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-hydroxypropyl]piperazine;
(62) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[3-(imidazol-1-yl)-1-phenylpropyl]piperazine;
(63) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-hydroxy-2-phenylpropyl)piperazine;
20 (64) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-methoxy-2-phenylpropyl)piperazine;
(65) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)-3-hydroxypropyl]piperazine;
25 (66) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)prop-2-yl]piperazine;
(67) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)propyl]piperazine;
(68) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-hydroxyprop-2-yl]piperazine;
30 (69) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-methoxyprop-2-yl]piperazine;
(70) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)-ethyl]piperazine;

- (71) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(2-fluorophenyl)-ethyl]piperazine;
- (72) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)-ethyl]piperazine;
- 5 (73) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-methoxyphenyl)-ethyl]piperazine;
- (74) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-trifluoromethyl-phenyl)ethyl]piperazine;
- 10 (75) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3,4-difluorophenyl)-ethyl]piperazine;
- (76) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(2,4-difluorophenyl)-ethyl]piperazine;
- (77) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3,5-difluorophenyl)-ethyl]piperazine;
- 15 (78) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-oxazolidin-2-on-3-yl)phenyl]ethyl]piperazine;
- (79) N-methyl-3-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl]pyrrolidine;
- 20 (80) N-methyl-4-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl]piperidine;
- (81) N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl]ethylamine;
- (82) 4-(1-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 25 (83) 4-(α -isopropoxy)phenylmethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- (84) 4-(α -methoxy)phenylmethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 30 (85) 4-[α -(2-methoxyethyl)oxy]phenylmethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- (86) 4-benzyl-1-[3-(2,3-dihydro-5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;

- (87) 1-[3-(2,3-dihydro-5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(pyridin-3-ylmethyl)piperazine;
- (88) 1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)-4-methylpiperazin-1-yl]piperidine;
- 5 (89) 1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]-3(*R*)-(3(*R*)-phenylmorpholin-4-ylmethyl)pyrrolidine;
- (90) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-oxo-2-phenylpiperazin-1-yl)methylpiperidine;
- (91) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(4-methyl-2-phenylpiperazin-1-yl)piperidine;
- 10 (92) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(benzimidazol-2-on-1-yl)piperidine;
- (93) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[6-(4-fluorophenyl)-4-methyl-3-oxopiperazin-1-yl]piperidine;
- 15 (94) [3-(3-(4-(2-(3,4-difluorophenyl)ethyl)piperazin-1-yl)propyl)-1*H*-indol-5-ylmethyl]oxazolidin-2-one;
- (95) (*S*)-4-[3-(3-(4-(2-(3,4-difluorophenyl)ethyl)piperazin-1-yl)propyl)-1*H*-indol-5-ylmethyl]-3-methyloxazolidin-2-one;
- (96) 1-[3-(5-(*N*-methylaminosulphonylmethyl)-1*H*-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
- 20 (97) 3-benzyl-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- (98) 3-(pyridin-3-yl)methyl-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- 25 (99) 3-[2-(4-(acetylamino)phenyl)ethyl]-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- (100) 3-benzoyl-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- (101) (1*RS*,3*RS*,5*RS*)-7-benzyl-3-[5-(imidazol-1-yl)-1*H*-indol-3-ylmethyl]-2-methyl-2,7-diazabicyclo[3.3.0]octane;
- 30 (102) (1*RS*,3*RS*,5*RS*)-7-[2-(3-fluorophenyl)ethyl]-2-methyl-3-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-ylmethyl]-2,7-diazabicyclo[3.3.0]octane;

- (103) (1*RS*,3*RS*,5*RS*)-7-(4-fluorobenzyl)-2-methyl-3-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-ylmethyl]-2,7-diazabicyclo-[3.3.0]octane;
- 5 (104) 4-[1-(phenyl)-*N,N*-dimethylcarboxamidomethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (105) 4-(2-methoxycarbonylamino-1-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (106) 4-(2-dimethylamino-1-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 10 (107) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(4-fluorophenyl)methylpiperazine;
- (108) 4-[2-(*N*-methyl-*N*-methoxycarbonyl)amino-1-phenylethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 15 (109) 1-benzyl-4-[(*R,S*)-2-hydroxymethyl-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (110) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(1*H*-tetrazol-5-yl)phenyl]methylpiperazine;
- (111) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine;
- 20 (112) 4-benzyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (113) 4-[2-(2-methyltetrazol-5-yl)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 25 (114) 4-[2-(1-methyltetrazol-5-yl)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (115) 4-[2-(*N*-methylcarboxamido)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (116) 4-[2-(*N,N*-dimethylaminomethyl)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 30 (117) 4-(but-3-enyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (118) 4-(3-methylbut-2-enyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;

- (119) 4-(prop-2-enyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- (120) 4-(prop-2-ynyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- 5 (121) 4-[(R,S)-1-(phenyl)carboxamidomethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- (122) 4-[1-(phenyl)-N-methylcarboxamidomethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- (123) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
- 10 (124) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(3-(acetylamino)phenyl)ethyl]piperazine;
- (125) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[4-(aminosulphonyl)phenyl]methylpiperazine;
- 15 (126) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(furan-3-yl)methylpiperazine;
- (127) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(furan-2-yl)methylpiperazine;
- (128) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(thien-2-yl)methylpiperazine;
- 20 (129) 1-benzyl-4-[(R,S)-2-hydroxy-3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- (130) 1-[2-(4-(acetylamino)phenyl)ethyl]-4-[(R,S)-2-hydroxy-3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- 25 (131) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(aminocarbonylamino)phenyl)ethyl]piperazine;
- (132) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(4-cyanophenyl)methylpiperazine;
- (133) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-cyanophenyl)ethyl]piperazine;
- 30 (134) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(1,2,4-triazol-4-yl)phenyl)ethyl]piperazine;
- (135) 1-[3-(5-(1,2,4-triazol-1-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;

- (136) 1-[3-(5-(1,2,4-triazol-1-yl)-1H-indol-3-yl)propyl]-4-benzylpiperazine;
- (137) 1-[3-(5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl)propyl]-4-benzylpiperazine;
- 5 (138) 4-(4-acetylaminophenyl)methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (139) 4-benzyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 10 (140) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(2-aminopyridin-5-yl)methylpiperazine;
- (141) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(4-aminophenyl)methylpiperazine;
- (142) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-benzylpiperazine;
- 15 (143) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-(pyridin-2-yl)methylpiperazine;
- (144) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-(pyridin-3-yl)methylpiperazine;
- (145) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-aminophenyl)ethyl]piperazine;
- 20 (146) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
- (147) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(imidazol-2-yl)methylpiperazine;
- 25 (148) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[3-(acetylamino)phenyl]methylpiperazine;
- (149) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[4-(acetylamino)phenyl]methylpiperazine;
- (150) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-[4-(acetylamino)phenyl]methylpiperazine;
- 30 (151) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(2-methoxyphenyl)methylpiperazine;
- (152) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-benzylpiperazine;

- (153) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(pyridin-3-yl)methylpiperazine;
- (154) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(pyridin-2-yl)methylpiperazine;
- 5 (155) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(pyridin-4-yl)methylpiperazine;
- (156) (3*R*)-3-benzyloxymethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (157) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 10 (158) (2*S*)-2-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (159) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 15 (160) 4-(4-acetylaminophenyl)methylamino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (161) 1-[3-(5-(imidazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(methoxymethyl)benzylamino]piperidine;
- (162) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1*H*-indol-3-yl)propyl]-4-[(*R*)-1-(4-fluorophenyl)-2-methoxyethylamino]piperidine;
- 20 (163) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1*H*-indol-3-yl)propyl]-4-[*N*-(4-fluorobenzyl)-*N*-methylamino]piperidine;
- (164) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(2-phenylpiperidin-1-yl)piperidine;
- 25 (165) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)-1-(4-fluorophenyl)-2-methoxyethylamino]piperidine;
- (166) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(indan-1-ylaminomethyl)piperidine;
- (167) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(*R*)- α -(hydroxymethyl)benzyl-*N*-methylaminomethyl]piperidine;
- 30 (168) (3*R*)-3-(benzylthio)methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- (169) (\pm)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(1-benzylamino-2-hydroxyethyl)piperidine;
- (170) 1-[3-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]piperidine;
- 5 (171) 1-[3-(5-(imidazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(methyl)benzylamino]piperidine;
- (172) 1-[3-(5-(imidazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]piperidine;
- (173) 1-[3-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]piperidine;
- 10 (174) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(methoxymethyl)benzylamino]piperidine;
- (175) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(*R*)- α -(methoxymethyl)benzyl-*N*-methylamino]piperidine;
- 15 (176) (3*R*)-3-benzyloxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (177) (3*R*)-3-(4-methoxyphenyl)methoxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (178) (3*R*)-3-(pyridin-3-yl)methoxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 20 (179) (3*R*)-3-benzyloxymethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (180) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 25 (181) (2*S*)-2-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (182) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (183) 4-(4-acetylaminophenyl)methylamino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 30 (184) 4-benzylamino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (185) 4-(*N*-benzyl-*N*-methyl)amino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;

- (186) 4-(*N*-benzyl-*N*-methyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (187) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[α -(methyl)benzylamino]piperidine;
- 5 (188) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[α -(hydroxymethyl)benzylamino]piperidine;
- (189) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1-hydroxymethyl-2-phenyl)ethylamino]piperidine;
- (190) 4-(*N*-benzyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (191) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(2-hydroxy-1-methyl-2-phenyl)ethylamino]piperidine;
- (192) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-acetylaminophenyl)ethylamino]piperidine;
- 15 (193) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[α -(methyl)benzylamino]methylpiperidine;
- (194) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-acetylaminophenyl)ethylamino]methylpiperidine;
- (195) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-[α -(hydroxymethyl)benzyl]-*N*-methylamino]piperidine;
- 20 (196) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(2-(4-acetylaminophenyl)ethyl)-*N*-methylamino]piperidine;
- (197) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(4-acetylaminobenzyl)-*N*-methylamino]methylpiperidine;
- 25 (198) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(thien-2-yl)methyl-*N*-methylamino]piperidine;
- (199) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]methylpiperidine;
- (200) 3-(4-acetylaminobenzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 30 (201) (3*R*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (202) (3*S*)-3-(pyridin-4-ylmethyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- (203) 3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]azetidine;
- (204) 4-benzyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 5 (205) 3-(*N*-benzyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]azetidine;
- (206) 4-(*N*-benzyl)aminomethyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (207) 4-(*N*-benzyl-*N*-methyl)aminomethyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (208) 3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]azetidine;
- (209) (3*S*)-3-[*N*- α -(methyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 15 (210) (3*S*)-3-[*N*-(furan-3-ylmethyl)amino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (211) (3*S*)-3-[*N*-(furan-2-ylmethyl)amino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (212) (3*S*)-3-[*N*- α -(hydroxymethyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 20 (213) (3*S*)-3-[*N*-benzyl-*N*-(2-hydroxy)ethyl]aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (214) (3*S*)-3-[*N*-(2-phenylethyl)amino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 25 -(215) (3*S*)-3-[*N*-(2-phenylethyl)-*N*-methylamino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (216) (3*S*)-3-(*N*- α -dimethylbenzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (217) (3*S*)-3-[*N*-(*S*)- α -methylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 30 (218) (3*S*)-3-[*N*-(*R*)- α -(hydroxymethyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (219) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- 5
10
15
20
25
30
- (220) (3*S*)-3-[*N*-(*S*)- α -methylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(221) (3*S*)-3-[*N*-(*R*)- α -(hydroxymethyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]-pyrrolidine;
(222) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(imidazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(223) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(224) (3*R*)-3-[*N*-methyl-*N*-(*S*)- α -methylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]-pyrrolidine;
(225) (3*R*)-3-[*N*-methyl-*N*-(*R*)- α -hydroxymethylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(226) (3*R*)-3-[*N*-methyl-*N*-(*S*)- α -methylcyclohexylmethyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(227) (3*R*)-3-[3-(*R*)-hydroxy-2-(*R*)-phenylpiperidin-1-yl]methyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]-pyrrolidine;
(228) (3*R*)-3-[3-(*R*)-hydroxy-2-(*R*)-phenylpiperidin-1-yl]methyl-1-[2-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(229) 4-hydroxy-4-(phenylsulfinyl)methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
(230) (3*R*)-3-[2-(*R,S*)-phenylpiperidin-1-yl]methyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(231) 4-(3,3-dimethylpiperidin-1-yl)methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
(232) 4-hydroxy-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
(233) 4-hydroxy-4-(*N*-isobutyl-*N*-methyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;

- (234) 4-[*N*-benzyl-*N*-(2-hydroxyethyl)amino]methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 5 (235) 4-[*N*-(2,2-dimethylpropyl)-*N*-methylamino]methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (236) 4-[*N*-(*R*)- α -hydroxymethylbenzyl-*N*-methylamino]methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (237) 4-hydroxy-4-(2-pyridylmethyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (238) 4-hydroxy-4-(2-methylphenylmethyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 15 (239) 4-hydroxy-4-[*N*-(2-methylphenylmethyl)-*N*-methylamino]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (240) 3-(benzylamino)methyl-3-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]pyrrolidine;
- (241) 3-(benzylamino)methyl-3-hydroxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 20 (242) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(carbamoyl-oxymethyl)benzylamino]piperidine;
- (243) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1*R*,2*S*)-2-hydroxy-1-phenylpropylamino]piperidine;
- 25 (244) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1*R*,2*R*)-2-hydroxy-1-phenylpropylamino]piperidine;
- (245) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*,*S*)-1-hydroxy-2-phenylprop-2-ylamino]piperidine;
- 30 (246) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)-2-hydroxy-1-(4-fluorophenyl)ethylamino]piperidine;
- (247) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1*R*,2*R*)-2-hydroxyindan-1-ylamino]piperidine;
- (248) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*,*S*)-indan-1-ylamino]piperidine;


- (249) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R,S*)-1-(4-fluorophenyl)ethylamino]piperidine;
- (250) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)-1-phenylprop-2-ylamino]piperidine;
- 5 (251) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(thien-3-ylmethyl)-*N*-methylamino]piperidine;
- (252) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(furan-3-ylmethyl)-*N*-methylamino]piperidine;
- (253) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(furan-3-ylmethyl)aminopiperidine;
- 10 (254) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N,N*-di-(furan-3-ylmethyl)amino]piperidine;
- (255) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(3,3-dimethylallyl)-*N*-methylamino]piperidine;
- 15 (256) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(*N*-allyl-*N*-methylamino)piperidine;
- (257) *N,N*-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- (258) *N,N*-Dimethyl-2-[5-(1,3-imidazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- 20 (259) *N,N*-Dimethyl-2-[5-(5-methyl-1,2,3,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- (260) *N,N*-Dimethyl-2-[5-(1,3,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- 25 (261) *N,N*-Dimethyl-2-[5-(1,3,4-triazol-1-yl)-1*H*-indol-3-yl]ethylamine;
- (262) *N,N*-Diethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- (263) *N,N*-Diethyl-2-[5-(1,3-imidazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- 30 (264) *N,N*-Diethyl-2-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
- (265) *N,N*-Diethyl-2-[5-(1,3,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;

- (266) N,N-Diethyl-2-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]ethylamine;
- (267) N,N-Dimethyl-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- 5 (268) N,N-Dimethyl-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- (269) N,N-Dimethyl-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- (270) N,N-Dimethyl-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- 10 (271) N,N-Dimethyl-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]methylamine;
- (272) N,N-Diethyl-3-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]propylamine;
- 15 (273) N,N-Dimethyl-3-[5-(1,3-imidazol-1-yl)-1H-indol-3-yl]propylamine;
- (274) N,N-Diethyl-3-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]propylamine;
- (275) N,N-Dimethyl-3-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]propylamine;
- 20 (276) N,N-Diethyl-3-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]propylamine;
- (277) N,N-Dimethyl-4-[5-(3-methyl-1,2,4,5-tetrazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
- 25 (278) N,N-Dimethyl-4-[5-(2-ethyl-1,3-ethyl-imidazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
- (279) N,N-Dimethyl-4-[5-(5-ethyl-1,2,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
- (280) N,N-Dimethyl-4-[5-(2-methyl-1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
- 30 (281) N,N-Dimethyl-4-[5-(2-ethyl-1,3,4-triazol-1-yl)-1H-indol-3-yl]butylamine;
- (282) 2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
- (283) 2-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;


- (284) 2-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
(285) 2-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
(286) 2-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]ethylalcohol;
5 (287) [5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-methanol;
(288) 3-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]propylalcohol;
(289) 4-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]butylalcohol;
10 (290) 2-[5-(2-methyl-1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol; and
(291) 2-[5-(5-methyl-1,3,4-triazol-1-yl)-1H-indol-3-yl]ethylalcohol.

15 Further 2-unsubstituted indoles which may be made according to the process of the present invention include:




(1)




(2)




20



5




, and




Preferred compounds that may be prepared according to the process of the present invention include:

(1)




5

(2)




(3)




10


(4)



(5)




(6)




, and

5


(7)



Still further, the present invention is also directed to the
 10 novel intermediates of structural formulae (V) and (VI).




V



VI

wherein Y, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are as defined above.

The acyl silanes employed in the present invention may be generally prepared according to the scheme below:



5 To TMS dithiane 1 in dry, polar aprotic solvent, such as THF, diethylether, t-butylmethylether, dioxane, diethoxymethane, is added an equivalent of a base such as lithium diisopropyl amide, NaH, Grignard, or an alkyl lithium, such as n-butyl lithium dropwise. Preferably, this alkylation is conducted at reduced temperatures, most
 10 preferably at -78 °C. Following the addition, the mixture is preferably warmed to -20 °C and aged at -20 °C for 0.5 h. Following aging, the reaction is preferably cooled to -78 °C. Br-CH₂-R⁸ 2, preferably dissolved in a small volume of the solvent, is added dropwise. The mixture is warmed, preferably to room temperature, and aged,
 15 preferably for about 12 hours. The mixture is partitioned between a lipophilic solvent, such as heptane, and water. The heptane layer is separated and concentrated in vacuum to give the dithiane 3 as a pale yellow oil. This material may be directly used in the next step.

A mixture of the dithiane 3, mercuric oxide and mercuric
 20 chloride in acetonitrile-H₂O, (preferably an 80:20 ratio) in an aprotic solvent such as ethyl acetate, isopropyl acetate, methylene chloride, acetonitrile, toluene and the like, is aged at room temperature, preferably for about 30 minutes. Alternatively, iodine in calcium carbonate may be employed. The resulting solid is filtered and washed,
 25 preferably with an aprotic solvent such as ethyl acetate, isopropyl acetate, methylene chloride, acetonitrile, toluene and the like. The filtrate and wash are combined and concentrated to an oil. This material may be chromatographed over silica gel to give the acyl silane 4 as a pale yellow oil.

Additional syntheses of acyl silanes which may be used to prepare starting materials for the compounds of the present invention are described in the following references:

- (1) Ricci et al., Synthesis 1989, pp. 647-660.
- 5 (2) Page et al., Chem. Soc. Rev. 1990, vol. 19, pp. 147-195.
- (3) Cirillo et al., Org. Prep. Proc. Int. 1992, vol. 24, pp. 555-582.
- 10 (4) Plantier-Royon and Portella, Tetrahedron Letters 1996, vol. 37 (34), pp. 6113-6114.


The following examples are not intended to be limitations on the scope of the instant invention in any way, and they should not be so construed. Furthermore, the compounds described in the following examples are not to be construed as forming the only genus that is
15 considered as the invention, and any combination of the compounds or their moieties may itself form a genus. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.

20

EXAMPLES

EXAMPLE 1







25 Preparation of 2-trimethylsilyl indole




A mixture of iodoaniline (2.19 g, 10 mmol), acyl silane (2.36 g, 20 mmol, prepared according to the procedures of reference example A), DABCO (1,4-diazabicyclo[2.2.2]octane, 3.36 g, 30 mmol) and Pd(OAc)₂ (112.25 mg, 0.5 mmol) in 30 mL DMF was degassed via N₂/vacuum and heated at 105°C for 36 h. The mixture was cooled to room temperature, diluted with IPAc (isopropyl acetate, 100 mL) and washed with 2X50 mL of water. The IPAc layer was concentrated in vacuum and chromatographed over silica gel to give 2-trimethylsilyl indole and indole.

EXAMPLES 2 TO 8

According to the procedures of Example 2, starting with the appropriately substituted 2-iodo aniline, and the appropriate acyl silane, the following compounds are prepared:

Example	Aniline	Acyl silane	Product
2			
3			



wherein R¹⁷ is a hydroxy protecting group that is removable under mild acid hydrolysis.











EXAMPLE 9**Preparation of Indole**

A mixture of the 2-trimethylsilyl indole product of Example 1 (0.50 g, 2.6 mmol) in 5 mL methanol was treated with 2.5 N HCl (2.11 mL, 5.2 mmol) and the reaction mixture was aged at room temperature for 2 h. Isopropyl acetate (50 mL) and water (10 mL) were then added. The layers were separated and the organic layer was concentrated under vacuum. The residual oil was chromatographed over silica gel to afford the indole as a white solid.


EXAMPLES 10-16

According to the procedure of Example 9 and employing the appropriate 2-trimethylsilyl indole product prepared according to the procedures of Examples 2 through 8, the following 2-unsubstituted indoles are prepared.

Example	2-TMS-indole	Indole Product
10		
11		

12		
13		
14		
15		
16		

wherein R¹⁷ is a hydroxy protecting group that is removable under mild acid hydrolysis.

REFERENCE EXAMPLE APreparation of O-t-butyldimethylsilyl-2,2-dimethyl-2-sila-hexan-3-one-6-ol

5

To 5 g (25.98 mmol) of TMS dithiane **1** in 70 mL dry THF at -78 °C was added n-BuLi (1.6 M, 16.25 mL, 26 mmol) dropwise. The mixture was warmed to -20 °C and aged at -20 °C for 0.5 h and cooled to -78 °C. Bromoether **2** in 5 mL of THF was added dropwise. The mixture was warmed to room temperature and aged for 12 h. It was partitioned between heptane (250 mL) and water (200 mL). The heptane layer was separated and concentrated under vacuum to give the dithiane **3** as a pale yellow oil. A portion of this material was directly used in the next step.

10


A mixture of dithiane **3** (4.0 g, 11 mmol), mercuric oxide (8.0 g) and mercuric chloride (8.0 g) in acetonitrile-H₂O (80:20, 30 mL) and ethyl acetate (10 mL) was aged at room temperature for 0.5 h. The solid was filtered and washed with ethyl acetate (40 mL). The filtrate and wash were combined and concentrated to an oil. This

material was chromatographed over silica gel to give the acyl silane 4 as a pale yellow oil.

5 While the invention has been described and illustrated with
reference to certain particular embodiments thereof, those skilled in the
art will appreciate that various changes, modifications and substitutions
can be made therein without departing from the spirit and scope of the
invention. It is intended, therefore, that the invention be defined by the
scope of the claims which follow and that such claims be interpreted as
10 broadly as is reasonable.

WHAT IS CLAIMED IS:

1. A process for preparing a compound of structural formula III:




III

wherein:

R^1 , R^2 , R^3 , R^4 , and R^8 are each substituents that will not interfere with the reaction conditions; and


R^5 , R^6 , and R^7 each represent C_{1-6} alkyl, $-O-C_{1-6}$ alkyl, or phenyl;

comprising reacting a compound of structural formula I with an acylsilane of structural formula II:



I

+



II


wherein:

Y is selected from Br, I and triflate, and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are as defined above; in the presence of a palladium catalyst and a proton acceptor.

2. The process according to Claim 1 wherein:
 Y is selected from Br, I and triflate;
 R¹, R², R³ and R⁴ are each independently selected from:

(1) hydrogen;



(3) C1-6 alkyl;

(4) $-(\text{CH}_2)_n - \text{Z}$

wherein Z represents:

(a) hydrogen,

(b) halogen,

(c) cyano,

(d) nitro,

(e) trifluoromethyl,

(f) $-\text{OR}^{10}$,

(g) $-\text{OCOR}^{10}$,

(h) $-\text{OCONR}^{10}\text{R}^{11}$,

(i) $-\text{OCH}_2\text{CN}$,

(j) $-\text{OCH}_2\text{CONR}^{10}\text{R}^{11}$,

(k) $-\text{SR}^{10}$, provided that R¹⁰ is not hydrogen,

(l) $-\text{SOR}^{10}$,

(m) $-\text{SO}_2\text{R}^{10}$,

(n) $-\text{SO}_2\text{NR}^{10}\text{R}^{11}$,

(o) $-\text{NR}^{10}\text{R}^{11}$,

(p) $-\text{NR}^{10}\text{COR}^{11}$,

(q) $-\text{NR}^{10}\text{CO}_2\text{R}^{11}$,


(r) $-\text{NR}^{10}\text{SO}_2\text{R}^{11}$,

(s) $-\text{COR}^{10}$,


(t) $-\text{CO}_2\text{R}^{10}$,

(u) $-\text{CONR}^{10}\text{R}^{11}$,


or Z is a group of formula (Za), (Zb), (Zc), or (Zd):




(Za)



(Zb)



(Zc)



(Zd)

or Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole;

R⁵, R⁶, and R⁷ are each independently selected from:

- (1) C₁₋₆ alkyl,
- (2) -O-C₁₋₆ alkyl, and
- (3) phenyl;

R⁸ is selected from:

- (1) hydrogen,
- (2) -R¹⁹-OH,
- (3) -R¹⁹-O-R¹⁷, and
- (4) -R¹⁹NR¹²R¹³, and
- (5) -R¹⁹-Z¹

wherein: Z¹ is a 3 to 7 membered heterocyclic ring wherein the ring members are selected from 1 to 2 nitrogen atoms and wherein the heterocyclic ring may be substituted by one or more R¹⁴;

R⁹ is selected from:

- (1) hydrogen, and
- (2) C₁₋₄ alkyl;

R¹⁰ and R¹¹ are each independently selected from:

- (1) hydrogen,

- (2) C₁₋₆ alkyl,
(3) trifluoromethyl,
(4) phenyl, optionally substituted with one or more R²⁰ substituents
5 (5) methylphenyl, optionally substituted with one or more R²⁰ substituents, and
(6) an arylC₁₋₆alkyl- or heteroaryl C₁₋₆alkyl- group, optionally substituted with one or more R²⁰ substituents, or
10 R¹⁰ and R¹¹ when linked through a nitrogen atom, together represent the residue of an optionally substituted azetidine, pyrrolidine, piperidine, morpholine or piperazine ring, optionally substituted with one or more R¹⁸ substituents;
15 R¹² and R¹³ are each independently selected from:
(1) C₁₋₄ alkyl,
(2) C₆aryl-C₁₋₄ alkyl- wherein aryl may be unsubstituted or substituted with one to three substituents selected from methyl, halo, and
20 halomethyl,
R¹⁴ is selected from:
(1) aryl-C₁₋₆alkyl-, unsubstituted or substituted with one to three R²⁰ substituents, and
(2) heteroaryl-C₁₋₆alkyl-, unsubstituted or substituted
25 with one to three R²⁰ substituents,
R¹⁵ and R¹⁶ are each independently selected from
(1) hydrogen,
(2) C₁₋₆alkyl,
(3) C₃₋₇cycloalkyl,
30 (4) C₃₋₇cycloalkylC₁₋₆alkyl-,
(5) indanyl,
(6) aryl,
(7) arylC₁₋₆alkyl-,
(8) C₃₋₇heterocycloalkyl-,

- (9) C₃₋₇heterocycloalkylC₁₋₆alkyl-,
- (10) heteroaryl, and
- (11) heteroarylC₁₋₆alkyl-;

5 R¹⁷ is selected from a hydroxy protecting group that is removable under mild acid hydrolysis;

R¹⁸ is selected from:


- (1) C₁₋₆alkyl-,
- (2) arylC₁₋₆alkyl-,
- (3) C₁₋₆alkoxy-,
- 10 (4) C₂₋₆alkyoxycarbonyl-, and
- (5) C₁₋₆alkylaminocarbonyl-;

R¹⁹ is a straight or branched C₁₋₆alkyl chain;

R²⁰ is selected from:

- (1) fluoro,
- 15 (2) cyano,
- (3) trifluoromethyl,
- (4) C₁₋₆alkyl,
- (5) haloC₁₋₆alkyl-,
- (6) aryl,
- 20 (7) triazolyl,
- (8) tetrazolyl,
- (9) tetrazolyl-C₁₋₆alkyl-,
- (10) hydroxy,
- (11) C₁₋₆alkoxy-,
- 25 (12) C₁₋₆alkylthio-,
- (13) C₂₋₆alkoxycarbonyl-,
- (14) C₂₋₆alkylcarbonyl-,
- (15) C₁₋₆alkylsulphonyl-,
- (16) arylsulfonyl-,
- 30 (17) C₂₋₆alkylcarbonylamino-,
- (18) arylcarbonylamino-,
- (19) C₂₋₆alkoxycarbonylamino-,
- (20) N-C₁₋₆alkyl-N-C₂₋₆alkoxyamino-,

- (21) carbonylamino-,
 (22) mono- or diarylamino carbonylamino-,
 (23) pyrrolidinyl carbonylamino-,
 (24) piperidinyl carbonylamino-,
 5 (25) aminocarbonyl-,
 (26) aminocarbonylamino-,
 (27) C₁-6alkylaminocarbonyl-,
 (28) C₁-6alkylaminocarbonylamino-,
 (29) diC₁-6alkylaminocarbonyl-,
 10 (30) diC₁-6alkylaminocarbonylamino-,
 (31) pyrrolidinyl carbonylamino-,
 (32) piperidinyl carbonylamino-,
 (33) aminosulfonyl-,
 (34) C₁-6alkylaminosulfonyl-,
 15 (35) C₁-6alkylsulfonylamino-,
 (36) C₁-6alkylsulfonylaminomethyl-,
 (37) arylsulfonylamino-,
 (38) diC₁-6alkylaminosulfonyl-,
 (39) aminosulphonylmethyl-,
 20 (40) C₁-6alkylaminosulphonylmethyl-,
 (41) diC₁-6alkylaminosulphonylmethyl-,
 (42) -(CH₂)_mOR¹⁵,
 (43) -(CH₂)_mSR¹⁵, provided that R¹⁵ is not hydrogen,
 (44) -(CH₂)_mSOR¹⁵,
 25 (45) -(CH₂)_mSO₂R¹⁵,
 (46) -(CH₂)_mNR¹⁵R¹⁶,
 (47) =O, and



30 X¹ and X² are each independently selected from ring nitrogen or ring carbon atoms;

X³ is selected from the group consisting of oxygen, sulfur, -NH- or methylene;

Y¹ is oxygen or sulfur;

n is an integer independently selected at each occurrence from 0 and 1; and

m is an integer selected independently at each occurrence from 0 to 4.

3. The process according to Claim 2 wherein R¹, R³, and R⁴ are each hydrogen.

4. The process according to Claim 1 wherein the palladium catalyst is selected from: a palladium alkanoate, a palladium acetate, a palladium halide, a palladium halide complex, a palladium-benzylidene acetone complex and a triarylphosphine palladium complex.

5. The process according to Claim 4 wherein the palladium catalyst is selected from: Pd(II) acetate, Pd(II) acetylacetonate, Pd(O)bis-dibenzylidene acetone ("dba"), Pd(II) bromide, Pd(II) chloride, Pd(II) iodide, Pd(II) sulfate, Pd(II)trifluoroacetate, Pd(II) Cl₂(CH₃CN)₂, Pd₂ (dba)₃, and Pd(II)Cl₂(PhCN)₂.

6. The process according to Claim 5 wherein the palladium catalyst is Pd(II) acetate.

7. The process according to Claim 1 wherein the proton acceptor does not interact with the palladium catalyst to inhibit its catalytic activity.

8. The process according to Claim 7 wherein the proton acceptor is selected from:

(a) an alkylamine,

- (b) an aromatic amine,
- (c) a heterocyclic amine, and
- (d) a phosphate.

5 9. The process according to Claim 8 wherein the proton acceptor is an alkylamine.

10 10. The process according to Claim 9 wherein the alkylamine is selected from:

- (a) 1,4-diazobicyclo[2.2.2]octane,
- (b) quinuclidine,
- (c) t-butylamine,
- (d) 2,2,6,6-tetramethylpiperidine, and
- (e) di-t-butylamine.

15 11. The process according to Claim 10 wherein the alkylamine is 1,4-diazobicyclo[2.2.2]octane.

20 12. The process according to Claim 1 wherein the reaction is carried out in a dry organic solvent inert for the starting materials.


25 13. The process according to Claim 12 wherein the solvent is selected from:

- (a) DMSO,
- (b) DMF,
- (c) DMAC, and
- (d) NMP.

30 14. The process according to Claim 13 wherein the solvent is DMF.

15. The process according to Claim 1 wherein the reaction is carried out at a temperature of 90 C° to 120 C°.

16. The process according to Claim 1 additionally comprising the step of deprotecting the compound of structural formula (III) to obtain the compound of structural formula (IV):



5

17. The process according to Claim 16 wherein the deprotection is a Lewis-acid catalyzed deprotection.

18. The process according to Claim 16 wherein:
 10 R^1 , R^2 , R^3 and R^4 are each independently selected from:

(1) hydrogen;

(2) $(CH_2)_n - N \begin{array}{c} \nearrow X^1-X^2 \\ \searrow R^9 \\ \text{---} N \end{array}$;

(3) C1-6 alkyl;

(4) $-(CH_2)_n-Z$

15

wherein Z represents:

(a) hydrogen,

(b) halogen,

(c) cyano,

(d) nitro,

20

(e) trifluoromethyl,

(f) OR^{10} ,


(g) $OCOR^{10}$,

(h) $OCONR^{10}R^{11}$,


(i) OCH_2CN ,

- (j) $\text{OCH}_2\text{CONR}^{10}\text{R}^{11}$,
 (k) SR^{10} , provided that R^{10} is not hydrogen,
 (l) SOR^{10} ,
 (m) SO_2R^{10} ,
 (n) $\text{SO}_2\text{NR}^{10}\text{R}^{11}$,
 (o) $\text{NR}^{10}\text{R}^{11}$,
 (p) $\text{NR}^{10}\text{COR}^{11}$,
 (q) $\text{NR}^{10}\text{CO}_2\text{R}^{11}$,
 (r) $\text{NR}^{10}\text{SO}_2\text{R}^{11}$,
 (s) COR^{10} ,
 (t) CO_2R^{10} ,
 (u) $\text{CONR}^{10}\text{R}^{11}$,


or Z is a group of formula (Za), (Zb), (Zc), or (Zd):




(Za)



(Zb)



(Zc)



(Zd)

or Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole;

R^5 , R^6 , and R^7 are each independently selected from:

- (1) C_{1-6} alkyl,
- (2) $-\text{O}-\text{C}_{1-6}$ alkyl, and
- (2) phenyl;

R^8 is selected from:

- (1) hydrogen,
- (2) $-\text{R}^{19}-\text{OH}$,

- (3) -R¹⁹-O-R¹⁷, and
- (4) -R¹⁹NR¹²R¹³, and
- (5) -R¹⁹-Z¹

wherein: Z¹ is a 3 to 7 membered heterocyclic ring wherein the ring members are selected from 1 to 2 nitrogen atoms and wherein the heterocyclic ring may be substituted by one or more R¹⁴;

R⁹ is selected from:

- (1) hydrogen, and
- (2) C₁₋₄ alkyl;

R¹⁰ and R¹¹ are each independently selected from:

- (1) hydrogen,
- (2) C₁₋₆ alkyl,
- (3) trifluoromethyl,
- (4) phenyl, optionally substituted with one or more R²⁰ substituents
- (5) methylphenyl, optionally substituted with one or more R²⁰ substituents, and
- (6) an arylC₁₋₆alkyl or heteroaryl C₁₋₆alkyl group, optionally substituted with one or more R²⁰ substituents, or

R¹⁰ and R¹¹ when linked through a nitrogen atom,

together represent the residue of an optionally substituted azetidine, pyrrolidine, piperidine, morpholine or piperazine ring, optionally substituted with one or more R¹⁸ substituents;

R¹² and R¹³ are each independently selected from:

- (1) C₁₋₄ alkyl,
- (2) C₁₋₄ alkyl-C₆aryl wherein aryl may be unsubstituted or substituted with one to three substituents selected from methyl, halo, and halomethyl,

R¹⁴ is selected from:

- (1) aryl-C₁-6alkyl, unsubstituted or substituted with one to three R²⁰ substituents, and
- (2) heteroaryl-C₁-6alkyl, unsubstituted or substituted with one to three R²⁰ substituents,

5 R¹⁵ and R¹⁶ are each independently selected from

- (1) hydrogen,
- (2) C₁-6alkyl,
- (3) C₃-7cycloalkyl,
- (4) C₃-7cycloalkylC₁-6alkyl,
- 10 (5) indanyl,
- (6) aryl,
- (7) arylC₁-6alkyl,
- (8) C₃-7heterocycloalkyl,
- (9) C₃-7heterocycloalkylC₁-6alkyl,
- 15 (10) heteroaryl, and
- (11) heteroarylC₁-6alkyl;

R¹⁷ is selected from a hydroxy protecting group that is removable under mild acid hydrolysis;

R¹⁸ is selected from:

- 20 (1) C₁-6alkyl,
- (2) arylC₁-6alkyl,
- (3) C₁-6alkoxy,
- (4) C₂-6alkyoxycarbonyl, and
- (5) C₁-6alkylaminocarbonyl;


25 R¹⁹ is a straight or branched C₁-6alkyl chain;

R²⁰ is selected from:

- (1) fluoro,
- (2) cyano,
- (3) trifluoromethyl,
- 30 (4) C₁-6alkyl,
- (5) haloC₁-6alkyl,
- (6) aryl,
- (7) triazolyl,

- 5 (8) tetrazolyl,
(9) C₁-6alkyl-tetrazolyl,
(10) hydroxy,
(11) C₁-6alkoxy,
(12) C₁-6alkylthio,
(13) C₂-6alkoxycarbonyl,
(14) C₂-6alkylcarbonyl,
(15) C₁-6alkylsulphonyl,
10 (16) arylsulfonyl,
(17) C₂-6alkylcarbonylamino,
(18) arylcarbonylamino,
(19) C₂-6alkoxycarbonylamino,
(20) N-C₁-6alkyl-N-C₂-6alkoxyamino,
(21) carbonylamino,
15 (22) mono- or diarylamino carbonylamino,
(23) pyrrolidinylcarbonylamino,
(24) piperidinylcarbonylamino,
(25) aminocarbonyl,
(26) aminocarbonylamino,
20 (27) C₁-6alkylaminocarbonyl,
(28) C₁-6alkylaminocarbonylamino,
(29) diC₁-6alkylaminocarbonyl,
(30) diC₁-6alkylaminocarbonylamino,
(31) pyrrolidinylcarbonylamino,
25 (32) piperidinylcarbonylamino,
(33) aminosulfonyl,
(34) C₁-6alkylaminosulfonyl,
(35) C₁-6alkylsulfonylamino,
(36) C₁-6alkylsulfonylaminomethyl,
30 (37) arylsulfonylamino,
(38) diC₁-6alkylaminosulfonyl,
(39) aminosulphonylmethyl,
(40) C₁-6alkylaminosulphonylmethyl, and
(41) diC₁-6alkylaminosulphonylmethyl,

- (42) $(\text{CH}_2)_m\text{OR}^{15}$,
 (43) $(\text{CH}_2)_m\text{SR}^{15}$, provided that R^{15} is not hydrogen,
 (44) $(\text{CH}_2)_m\text{SOR}^{15}$,
 (45) $(\text{CH}_2)_m\text{SO}_2\text{R}^{15}$,
 (46) $(\text{CH}_2)_m\text{NR}^{15}\text{R}^{16}$,
 (47) $=\text{O}$, and



X^1 and X^2 are each independently selected from ring nitrogen or ring carbon atoms;

X^3 is selected from the group consisting of oxygen, sulfur, $-\text{NH}-$ or methylene;

Y^1 is oxygen or sulfur;

n is an integer independently selected at each occurrence from 0 and 1; and

m is an integer selected independently at each occurrence from 0 to 4.

19. The process according to Claim 18 wherein R^1 , R^3 , and R^4 are each hydrogen.

20. The process according to Claim 19 wherein the compound according to structural formula IV is selected from:

- (1) 1-benzyl-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazin-2-one;
- (2) 1-(2-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazin-2-one;
- (3) 1-[2-(3-fluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazin-2-one;
- (4) (3S)-3-(N-benzyl)aminomethyl-1-[2-(5-(N-methyl)-aminosulphonylmethyl)-1H-indol-3-yl)ethyl]pyrrolidine;

- (5) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(aminosulphonylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (6) (3*S*)-3-(*N*-benzyl)aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 5 (7) (3*S*)-3-[*N*-(*R*)- α -(hydroxymethyl)benzyl]aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (8) (3*S*)-3-[*N*-(*S*)- α -methylbenzyl]aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 10 (9) 4-[*N*-(*R*)- α -(hydroxymethyl)benzyl]amino-(*S*)-1-[3-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)propyl]piperidine;
- (10) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-(*S*)-1-[2-(5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 15 (11) (3*R*)-3-[*N*-(*S*)- α -methylbenzyl-*N*-methyl]aminomethyl-(*S*)-1-[2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (12) (3*R*)-3-[*N*-(*S*)- α -methylbenzyl-*N*-methyl]aminomethyl-(*S*)-1-[2-(5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 20 (13) (3*S*)-3-[*N*-(4-fluorobenzyl)-*N*-methyl]aminomethyl-(*S*)-1-[2-(5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 25 (14) 4-benzyl-12-[2-fluoromethyl-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (15) 4-[2-(3-fluorophenyl)ethyl]-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 30 (16) 4-benzyl-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (17) 4-(*N*-benzyl-*N*-methylamino)-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;

- 5
- (18) 4-[(R)-2-hydroxy-1-(4-fluorophenyl)ethylamino]-1-[2-fluoro-3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (19) 7-benzyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (20) 7-(3-furylmethyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (21) 7-(2-phenylethyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- 10
- (22) 7-(4-fluorobenzyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (23) 7-(2,4-difluorobenzyl-2-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]-*cis*-2,7-diazabicyclo[3.3.0]octane;
- (24) 4-(2,2-difluoro-1-oxo-2-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
- 15
- (25) 4-benzyl-3-methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- (26) 4-benzyl-3-methoxymethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 20
- (27) 1-(2-hydroxy-1-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (28) 1-[2-(2-fluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (29) 1-benzyl-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- 25
- (30) 1-(3,3-dimethylbutyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (31) 1-(2-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- 30
- (32) 1-cyclohexylmethyl-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (33) 1-(3-phenylpropyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;

- (34) 1-[2-(3-fluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (35) 1-[2-(4-trifluoromethylphenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 5 (36) 1-[2-(3,4-difluorophenyl)ethyl]-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (37) *N*-methyl-2-phenyl-2-[4-(3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl)piperidin-1-yl]acetamide;
- (38) 1-(2-oxo-2-phenylethyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (39) 1-(2-phenylpropyl)-4-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (40) 4-benzyl-4-fluoro-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 15 (41) 4-fluoro-4-[2-(3-fluorophenyl)ethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (42) 4-fluoro-4-(3-fluorobenzyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (43) 4-fluoro-4-(2-fluorobenzyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 20 (44) 4-benzyl-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (45) 4-benzyl-4-methoxy-1-[3-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)propyl]piperidine;
- 25 (46) 4-(2-fluorobenzyl)-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (47) 4-(3-fluorobenzyl)-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (48) 4-(4-fluorobenzyl)-4-methoxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 30 (49) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(oxazol-2-on-3-yl)-1-phenylethyl]piperazine;
- (50) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(oxazolidin-2-on-3-yl)-1-phenylethyl]piperazine;

- 5 (51) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-(oxazolidin-2-on-3-yl)ethyl]piperazine;
- (52) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-hydroxy-1-phenylpropyl)piperazine;
- (53) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(imidazol-1-yl)-1-phenylethyl]piperazine;
- (54) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-hydroxyethyl]piperazine;
- 10 (55) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-methoxyethyl]piperazine;
- (56) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-phenylpropyl]piperazine;
- (57) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-benzyloxy-1-(4-fluorophenyl)ethyl]piperazine;
- 15 (58) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-methoxypropyl]piperazine;
- (59) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-2-(imidazol-1-yl)ethyl]piperazine;
- 20 (60) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-phenyl-2-(pyrrolidin-1-yl)ethyl]piperazine;
- (61) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-hydroxypropyl]piperazine;
- (62) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[3-(imidazol-1-yl)-1-phenylpropyl]piperazine;
- 25 (63) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-hydroxy-2-phenylpropyl)piperazine;
- (64) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-methoxy-2-phenylpropyl)piperazine;
- 30 (65) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)-3-hydroxypropyl]piperazine;
- (66) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)prop-2-yl]piperazine;
- (67) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)propyl]piperazine;

- (68) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-hydroxyprop-2-yl]piperazine;
- (69) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-fluorophenyl)-3-methoxyprop-2-yl]piperazine;
- 5 (70) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)-ethyl]piperazine;
- (71) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(2-fluorophenyl)-ethyl]piperazine;
- (72) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)-ethyl]piperazine;
- 10 (73) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-methoxyphenyl)-ethyl]piperazine;
- (74) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-trifluoromethyl-phenyl)ethyl]piperazine;
- 15 (75) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3,4-difluorophenyl)-ethyl]piperazine;
- (76) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(2,4-difluorophenyl)-ethyl]piperazine;
- (77) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3,5-difluorophenyl)-ethyl]piperazine;
- 20 (78) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(3-oxazolidin-2-on-3-yl)phenyl)ethyl]piperazine;
- (79) N-methyl-3-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl]pyrrolidine;
- 25 (80) N-methyl-4-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl]piperidine;
- (81) N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl]ethylamine;
- (82) 4-(1-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 30 (83) 4-(α -isopropoxy)phenylmethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- (84) 4-(α -methoxy)phenylmethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;

- 5
- (85) 4-[α -(2-methoxyethyl)oxy]phenylmethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- (86) 4-benzyl-1-[3-(2,3-dihydro-5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (87) 1-[3-(2,3-dihydro-5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(pyridin-3-ylmethyl)piperazine;
- (88) 1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)-4-methylpiperazin-1-yl]piperidine;
- 10
- (89) 1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]-3(*R*)-(3(*R*)-phenylmorpholin-4-ylmethyl)pyrrolidine;
- (90) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(3-oxo-2-phenylpiperazin-1-yl)methylpiperidine;
- (91) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(4-methyl-2-phenylpiperazin-1-yl)piperidine;
- 15
- (92) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(benzimidazol-2-on-1-yl)piperidine;
- (93) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[6-(4-fluorophenyl)-4-methyl-3-oxopiperazin-1-yl]piperidine;
- 20
- (94) [3-(3-(4-(2-(3,4-difluorophenyl)ethyl)piperazin-1-yl)propyl)-1*H*-indol-5-ylmethyl]oxazolidin-2-one;
- (95) (*S*)-4-[3-(3-(4-(2-(3,4-difluorophenyl)ethyl)piperazin-1-yl)propyl)-1*H*-indol-5-ylmethyl]-3-methyloxazolidin-2-one;
- (96) 1-[3-(5-(*N*-methylaminosulphonylmethyl)-1*H*-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
- 25
- (97) 3-benzyl-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- (98) 3-(pyridin-3-yl)methyl-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- 30
- (99) 3-[2-(4-(acetylamino)phenyl)ethyl]-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;
- (100) 3-benzoyl-7-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-*cis*-3,7-diazabicyclo[3.3.0]octane;

- 5
- (101) (1*RS*,3*RS*,5*RS*)-7-benzyl-3-[5-(imidazol-1-yl)-1*H*-indol-3-ylmethyl]-2-methyl-2,7-diazabicyclo[3.3.0]octane;
- (102) (1*RS*,3*RS*,5*RS*)-7-[2-(3-fluorophenyl)ethyl]-2-methyl-3-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-ylmethyl]-2,7-diazabicyclo[3.3.0]octane;
- (103) (1*RS*,3*RS*,5*RS*)-7-(4-fluorobenzyl)-2-methyl-3-[5-(1,2,4-triazol-4-yl)-1*H*-indol-3-ylmethyl]-2,7-diazabicyclo[3.3.0]octane;
- 10
- (104) 4-[1-(phenyl)-*N,N*-dimethylcarboxamidomethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (105) 4-(2-methoxycarbonylamino-1-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (106) 4-(2-dimethylamino-1-phenylethyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 15
- (107) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(4-fluorophenyl)methylpiperazine;
- (108) 4-[2-(*N*-methyl-*N*-methoxycarbonyl)amino-1-phenylethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 20
- (109) 1-benzyl-4-[(*R,S*)-2-hydroxymethyl-3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (110) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(1*H*-tetrazol-5-yl)phenyl]methylpiperazine;
- (111) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine;
- 25
- (112) 4-benzyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (113) 4-[2-(2-methyltetrazol-5-yl)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- 30
- (114) 4-[2-(1-methyltetrazol-5-yl)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;
- (115) 4-[2-(*N*-methylcarboxamido)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperazine;

- 5 (116) 4-[2-(N,N-dimethylaminomethyl)phenyl]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
(117) 4-(but-3-enyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
(118) 4-(3-methylbut-2-enyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
(119) 4-(prop-2-enyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
10 (120) 4-(prop-2-ynyl)-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
(121) 4-[(R,S)-1-(phenyl)carboxamidomethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
(122) 4-[1-(phenyl)-N-methylcarboxamidomethyl]-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
15 (123) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
(124) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(3-(acetylamino)phenyl)ethyl]piperazine;
(125) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[4-(aminosulphonyl)phenyl]methylpiperazine;
20 (126) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(furan-3-yl)methylpiperazine;
(127) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(furan-2-yl)methylpiperazine;
(128) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(thien-2-yl)methylpiperazine;
25 (129) 1-benzyl-4-[(R,S)-2-hydroxy-3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
(130) 1-[2-(4-(acetylamino)phenyl)ethyl]-4-[(R,S)-2-hydroxy-3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperazine;
30 (131) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(aminocarbonylamino)phenyl)ethyl]piperazine;
(132) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(4-cyanophenyl)methylpiperazine;

- (133) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-cyanophenyl)ethyl]piperazine;
- (134) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(1,2,4-triazol-4-yl)phenyl)ethyl]piperazine;
- 5 (135) 1-[3-(5-(1,2,4-triazol-1-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
- (136) 1-[3-(5-(1,2,4-triazol-1-yl)-1H-indol-3-yl)propyl]-4-benzylpiperazine;
- (137) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)propyl]-4-benzylpiperazine;
- 10 (138) 4-(4-acetylaminophenyl)methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (139) 4-benzyl-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-1,2,5,6-tetrahydropyridine;
- 15 (140) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(2-aminopyridin-5-yl)methylpiperazine;
- (141) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(4-aminophenyl)methylpiperazine;
- (142) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-benzylpiperazine;
- 20 (143) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-(pyridin-2-yl)methylpiperazine;
- (144) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-(pyridin-3-yl)methylpiperazine;
- 25 (145) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-aminophenyl)ethyl]piperazine;
- (146) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-(acetylamino)phenyl)ethyl]piperazine;
- (147) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(imidazol-2-yl)methylpiperazine;
- 30 (148) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[3-(acetylamino)phenyl]methylpiperazine;
- (149) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[4-(acetylamino)phenyl]methylpiperazine;

- (150) 1-[4-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)butyl]-4-[4-(acetylamino)phenyl]methylpiperazine;
- (151) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(2-methoxyphenyl)methylpiperazine;
- 5 (152) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-benzylpiperazine;
- (153) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(pyridin-3-yl)methylpiperazine;
- (154) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(pyridin-2-yl)methylpiperazine;
- 10 (155) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(pyridin-4-yl)methylpiperazine;
- (156) (3R)-3-benzyloxymethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]pyrrolidine;
- 15 (157) (3S)-3-(N-benzyl-N-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]pyrrolidine;
- (158) (2S)-2-(N-benzyl-N-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]pyrrolidine;
- (159) (3S)-3-(N-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]pyrrolidine;
- 20 (160) 4-(4-acetylamino)phenyl)methylamino-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidine;
- (161) 1-[3-(5-(imidazol-1-yl)-1H-indol-3-yl)propyl]-4-[(R)- α -(methoxymethyl)benzylamino]piperidine;
- 25 (162) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)propyl]-4-[(R)-1-(4-fluorophenyl)-2-methoxyethylamino]piperidine;
- (163) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)propyl]-4-[N-(4-fluorobenzyl)-N-methylamino]piperidine;
- (164) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(2-phenylpiperidin-1-yl)piperidine;
- 30 (165) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[(R)-1-(4-fluorophenyl)-2-methoxyethylamino]piperidine;
- (166) 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(indan-1-ylaminomethyl)piperidine;

- (167) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(*R*)- α -(hydroxymethyl)benzyl-*N*-methylaminomethyl]piperidine;
- 5 (168) (3*R*)-3-(benzylthio)methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (169) (\pm)-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(1-benzylamino-2-hydroxyethyl)piperidine;
- (170) 1-[3-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]piperidine;
- 10 (171) 1-[3-(5-(imidazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(methyl)benzylamino]piperidine;
- (172) 1-[3-(5-(imidazol-1-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]piperidine;
- (173) 1-[3-(5-(1,2,4-triazol-1-yl)methyl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]piperidine;
- 15 (174) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(methoxymethyl)benzylamino]piperidine;
- (175) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(*R*)- α -(methoxymethyl)benzyl-*N*-methylamino]piperidine;
- 20 (176) (3*R*)-3-benzyloxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (177) (3*R*)-3-(4-methoxyphenyl)methoxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (178) (3*R*)-3-(pyridin-3-yl)methoxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 25 (179) (3*R*)-3-benzyloxymethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (180) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 30 (181) (2*S*)-2-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (182) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- (183) 4-(4-acetylaminophenyl)methylamino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (184) 4-benzylamino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 5 (185) 4-(*N*-benzyl-*N*-methyl)amino-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (186) 4-(*N*-benzyl-*N*-methyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (187) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[α -(methyl)benzylamino]piperidine;
- 10 (188) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[α -(hydroxymethyl)benzylamino]piperidine;
- (189) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1-hydroxymethyl-2-phenyl)ethylamino]piperidine;
- 15 (190) 4-(*N*-benzyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (191) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(2-hydroxy-1-methyl-2-phenyl)ethylamino]piperidine;
- (192) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[2-(4-acetylaminophenyl)ethylamino]piperidine;
- 20 (193) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[α -(methyl)benzylamino]methylpiperidine;
- (194) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[1-(4-acetylaminophenyl)ethylamino]methylpiperidine;
- 25 (195) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-[α -(hydroxymethyl)benzyl]-*N*-methylamino]piperidine;
- (196) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(2-(4-acetylaminophenyl)ethyl)-*N*-methylamino]piperidine;
- (197) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(4-acetylaminobenzyl)-*N*-methylamino]methylpiperidine;
- 30 (198) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(thien-2-yl)methyl-*N*-methylamino]piperidine;
- (199) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(hydroxymethyl)benzylamino]methylpiperidine;

- (200) 3-(4-acetylaminobenzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (201) (3*R*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 5 (202) (3*S*)-3-(pyridin-4-ylmethyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (203) 3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]azetidine;
- (204) 4-benzyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (205) 3-(*N*-benzyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]azetidine;
- (206) 4-(*N*-benzyl)aminomethyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 15 (207) 4-(*N*-benzyl-*N*-methyl)aminomethyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (208) 3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]azetidine;
- (209) (3*S*)-3-[*N*- α -(methyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 20 (210) (3*S*)-3-[*N*-(furan-3-ylmethyl)amino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (211) (3*S*)-3-[*N*-(furan-2-ylmethyl)amino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 25 (212) (3*S*)-3-[*N*- α -(hydroxymethyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (213) (3*S*)-3-[*N*-benzyl-*N*-(2-hydroxy)ethyl]aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (214) (3*S*)-3-[*N*-(2-phenylethyl)amino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- 30 (215) (3*S*)-3-[*N*-(2-phenylethyl)-*N*-methylamino]methyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (216) (3*S*)-3-(*N*- α -dimethylbenzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- 5 (217) (3*S*)-3-[*N*-(*S*)- α -methylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(218) (3*S*)-3-[*N*-(*R*)- α -(hydroxymethyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(219) (3*S*)-3-(*N*-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(220) (3*S*)-3-[*N*-(*S*)- α -methylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
10 (221) (3*S*)-3-[*N*-(*R*)- α -(hydroxymethyl)benzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(222) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(imidazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(223) (3*S*)-3-(*N*-benzyl-*N*-methyl)aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
15 (224) (3*R*)-3-[*N*-methyl-*N*-(*S*)- α -methylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(225) (3*R*)-3-[*N*-methyl-*N*-(*R*)- α -hydroxymethylbenzyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
20 (226) (3*R*)-3-[*N*-methyl-*N*-(*S*)- α -methylcyclohexylmethyl]aminomethyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
(227) (3*R*)-3-[3-(*R*)-hydroxy-2-(*R*)-phenylpiperidin-1-yl]methyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
25 (228) (3*R*)-3-[3-(*R*)-hydroxy-2-(*R*)-phenylpiperidin-1-yl]methyl-1-[2-(5-(1,2,4-triazol-1-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
30 (229) 4-hydroxy-4-(phenylsulfinyl)methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
(230) (3*R*)-3-[2-(*R,S*)-phenylpiperidin-1-yl]methyl-1-[2-(5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl)ethyl]pyrrolidine;

- (231) 4-(3,3-dimethylpiperidin-1-yl)methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (232) 4-hydroxy-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 5 (233) 4-hydroxy-4-(*N*-isobutyl-*N*-methyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (234) 4-[*N*-benzyl-*N*-(2-hydroxyethyl)amino]methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 10 (235) 4-[*N*-(2,2-dimethylpropyl)-*N*-methylamino]methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (236) 4-[*N*-(*R*)- α -hydroxymethylbenzyl-*N*-methylamino]methyl-4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 15 (237) 4-hydroxy-4-(2-pyridylmethyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (238) 4-hydroxy-4-(2-methylphenylmethyl)aminomethyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- 20 (239) 4-hydroxy-4-[*N*-(2-methylphenylmethyl)-*N*-methylamino]methyl-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]piperidine;
- (240) 3-(benzylamino)methyl-3-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]pyrrolidine;
- 25 (241) 3-(benzylamino)methyl-3-hydroxy-1-[2-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)ethyl]pyrrolidine;
- (242) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)- α -(carbamoyl-oxymethyl)benzylamino]piperidine;
- (243) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1*R*,2*S*)-2-hydroxy-1-phenylpropylamino]piperidine;
- 30 (244) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1*R*,2*R*)-2-hydroxy-1-phenylpropylamino]piperidine;
- (245) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*,*S*)-1-hydroxy-2-phenylprop-2-ylamino]piperidine;


- 5 (246) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)-2-hydroxy-1-(4-fluorophenyl)ethylamino]piperidine;
(247) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(1*R*,2*R*)-2-hydroxyindan-1-ylamino]piperidine;
(248) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R,S*)-indan-1-ylamino]piperidine;
(249) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R,S*)-1-(4-fluorophenyl)ethylamino]piperidine;
10 (250) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[(*R*)-1-phenylprop-2-ylamino]piperidine;
(251) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(thien-3-ylmethyl)-*N*-methylamino]piperidine;
(252) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(furan-3-ylmethyl)-*N*-methylamino]piperidine;
15 (253) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(furan-3-ylmethyl)aminopiperidine;
(254) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N,N*-di-(furan-3-ylmethyl)amino]piperidine;
(255) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-[*N*-(3,3-dimethylallyl)-*N*-methylamino]piperidine;
20 (256) 1-[3-(5-(1,2,4-triazol-4-yl)-1*H*-indol-3-yl)propyl]-4-(*N*-allyl-*N*-methylamino)piperidine;
(257) *N,N*-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
25 (258) *N,N*-Dimethyl-2-[5-(1,3-imidazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
(259) *N,N*-Dimethyl-2-[5-(5-methyl-1,2,3,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
(260) *N,N*-Dimethyl-2-[5-(1,3,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;
30 (261) *N,N*-Dimethyl-2-[5-(1,3,4-triazol-1-yl)-1*H*-indol-3-yl]ethylamine;
(262) *N,N*-Diethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1*H*-indol-3-yl]ethylamine;

- (263) N,N-Diethyl-2-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;
- (264) N,N-Diethyl-2-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;
- 5 (265) N,N-Diethyl-2-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;
- (266) N,N-Diethyl-2-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]ethylamine;
- (267) N,N-Dimethyl-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- 10 (268) N,N-Dimethyl-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- (269) N,N-Dimethyl-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- 15 (270) N,N-Dimethyl-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]methylamine;
- (271) N,N-Dimethyl-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]methylamine;
- (272) N,N-Diethyl-3-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]propylamine;
- 20 (273) N,N-Dimethyl-3-[5-(1,3-imidazol-1-yl)-1H-indol-3-yl]propylamine;
- (274) N,N-Diethyl-3-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]propylamine;
- 25 (275) N,N-Dimethyl-3-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]propylamine;
- (276) N,N-Diethyl-3-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]propylamine;
- (277) N,N-Dimethyl-4-[5-(3-methyl-1,2,4,5-tetrazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
- 30 (278) N,N-Dimethyl-4-[5-(2-ethyl-1,3-ethyl-imidazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
- (279) N,N-Dimethyl-4-[5-(5-ethyl-1,2,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]butylamine;

- (280) N,N-Dimethyl-4-[5-(2-methyl-1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]butylamine;
(281) N,N-Dimethyl-4-[5-(2-ethyl-1,3,4-triazol-1-yl)-1H-indol-3-yl]butylamine;
5 (282) 2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
(283) 2-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
(284) 2-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
10 (285) 2-[5-(1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol;
(286) 2-[5-(1,3,4-triazol-1-yl)-1H-indol-3-yl]ethylalcohol;
(287) [5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-methylalcohol;
(288) 3-[5-(1,3-imidazol-1-ylmethyl)-1H-indol-3-yl]propylalcohol;
15 (289) 4-[5-(5-methyl-1,2,3,4-tetrazol-1-ylmethyl)-1H-indol-3-yl]butylalcohol;
(290) 2-[5-(2-methyl-1,3,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylalcohol; and
(291) 2-[5-(5-methyl-1,3,4-triazol-1-yl)-1H-indol-3-yl]ethylalcohol.
20


21. The process according to Claim 19 wherein the compound of structural formula IV is selected from:

(1)




25

(2)




(3)




5


(4)



(5)




(6)




10

, and

(7)



22. The compounds of structural formulae (V) and (VI):



wherein:

R^1 , R^2 , R^3 , R^4 , and R^8 are each substituents that will not interfere with the reaction conditions;

R^5 , R^6 , and R^7 each represent C1-6 alkyl, C1-6 alkyloxy- or phenyl; and

Y is selected from Br, I and triflate.

23. The compound of structural formula (V) or (VI) according to Claim 22 wherein:

Y is selected from Br, I and triflate;

R^1 , R^2 , R^3 and R^4 are each independently selected from:

(1) hydrogen;

(2) $(CH_2)_n - N \begin{array}{l} \nearrow X^1 - X^2 \\ \searrow \\ R^9 \end{array} = N$;


(3) C1-6 alkyl;

(4) $-(CH_2)_n-Z$


wherein Z represents:

- (a) hydrogen,
- (b) halogen,
- (c) cyano,
- (d) nitro,
- (e) trifluoromethyl,
- (f) OR^{10} ,
- (g) $OCOR^{10}$,
- (h) $OCONR^{10}R^{11}$,
- (i) OCH_2CN ,
- (j) $OCH_2CONR^{10}R^{11}$,
- (k) SR^{10} ,
- (l) SOR^{10} ,
- (m) SO_2R^{10} , provided that R^{10} is not hydrogen,
- (n) $SO_2NR^{10}R^{11}$,
- (o) $NR^{10}R^{11}$,
- (p) $NR^{10}COR^{11}$,
- (q) $NR^{10}CO_2R^{11}$,
- (r) $NR^{10}SO_2R^{11}$,
- (s) COR^{10} ,
- (t) CO_2R^{10} ,
- (u) $CONR^{10}R^{11}$,


or Z is a group of formula (Za), (Zb), (Zc), or (Zd):




(Za)



(Zb)



(Zc)



(Zd)

or Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene,

pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole;

5 R⁵, R⁶, and R⁷ are each independently selected from:

- (1) C₁₋₆ alkyl,
- (2) -O-C₁₋₆ alkyl, and
- (3) phenyl;

10 R⁸ is selected from:

- (1) hydrogen,
- (2) -R¹⁹-OH,
- (3) -R¹⁹-O-R¹⁷, and
- (4) -R¹⁹NR¹²R¹³, and
- (5) -R¹⁹-Z¹

15 wherein: Z¹ is a 3 to 7 membered heterocyclic ring wherein the ring members are selected from 1 to 2 nitrogen atoms and wherein the heterocyclic ring may be substituted by one or more R¹⁴;

20 R⁹ is selected from:

- (1) hydrogen, and
- (2) C₁₋₄ alkyl;

R¹⁰ and R¹¹ are each independently selected from:

- 25 (1) hydrogen,
- (2) C₁₋₆ alkyl,
- (3) trifluoromethyl,
- (4) phenyl, optionally substituted with one or more R²⁰ substituents
- 30 (5) methylphenyl, optionally substituted with one or more R²⁰ substituents, and
- (6) an arylC₁₋₆alkyl or heteroaryl C₁₋₆alkyl group, optionally substituted with one or more R²⁰ substituents, or

- 5 R¹⁰ and R¹¹ when linked through a nitrogen atom,
together represent the residue of an optionally
substituted azetidine, pyrrolidine, piperidine,
morpholine or piperazine ring, optionally substituted
with one or more R¹⁸ substituents;
- 10 R¹² and R¹³ are each independently selected from:
(1) C₁₋₄ alkyl,
(2) C₁₋₄ alkyl-C₆aryl wherein aryl may be unsubstituted
or substituted with one to three substituents selected
from methyl, halo, and halomethyl,
- 15 R¹⁴ is selected from:
(1) aryl-C₁₋₆alkyl, unsubstituted or substituted with one
to three R²⁰ substituents, and
(2) heteroaryl-C₁₋₆alkyl, unsubstituted or substituted
with one to three R²⁰ substituents,
- 20 R¹⁵ and R¹⁶ are each independently selected from
(1) hydrogen,
(2) C₁₋₆alkyl,
(3) C₃₋₇cycloalkyl,
(4) C₃₋₇cycloalkylC₁₋₆alkyl,
(5) indanyl,
(6) aryl,
(7) arylC₁₋₆alkyl,
(8) C₃₋₇heterocycloalkyl,
(9) C₃₋₇heterocycloalkylC₁₋₆alkyl,
(10) heteroaryl, and
(11) heteroarylC₁₋₆alkyl;
- 25 R¹⁷ is selected from a hydroxy protecting group that is
removable under mild acid hydrolysis;
- 30 R¹⁸ is selected from:
(1) C₁₋₆alkyl,
(2) arylC₁₋₆alkyl,
(3) C₁₋₆alkoxy,

(4) C₂-6alkyloxycarbonyl, and


(5) C₁-6alkylaminocarbonyl;

R¹⁹ is a straight or branched C₁-6alkyl chain;

R²⁰ is selected from:

- | | |
|----|---|
| 5 | (1) fluoro, |
| | (2) cyano, |
| | (3) trifluoromethyl, |
| | (4) C ₁ -6alkyl, |
| | (5) haloC ₁ -6alkyl, |
| 10 | (6) aryl, |
| | (7) triazolyl, |
| | (8) tetrazolyl, |
| | (9) C ₁ -6alkyl-tetrazolyl, |
| | (10) hydroxy, |
| 15 | (11) C ₁ -6alkoxy, |
| | (12) C ₁ -6alkylthio, |
| | (13) C ₂ -6alkoxycarbonyl, |
| | (14) C ₂ -6alkylcarbonyl, |
| | (15) C ₁ -6alkylsulphonyl, |
| 20 | (16) arylsulfonyl, |
| | (17) C ₂ -6alkylcarbonylamino, |
| | (18) arylcarbonylamino, |
| | (19) C ₂ -6alkoxycarbonylamino, |
| | (20) N-C ₁ -6alkyl-N-C ₂ -6alkoxyamino, |
| 25 | (21) carbonylamino, |
| | (22) mono- or diarylamino carbonylamino, |
| | (23) pyrrolidinylcarbonylamino, |
| | (24) piperidinylcarbonylamino, |
| | (25) aminocarbonyl, |
| 30 | (26) aminocarbonylamino, |
| | (27) C ₁ -6alkylaminocarbonyl, |
| | (28) C ₁ -6alkylaminocarbonylamino, |
| | (29) diC ₁ -6alkylaminocarbonyl, |

- (30) diC₁₋₆alkylaminocarbonylamino,
 (31) pyrrolidinylcarbonylamino,
 (32) piperidinylcarbonylamino,
 (33) aminosulfonyl,
 5 (34) C₁₋₆alkylaminosulfonyl,
 (35) C₁₋₆alkylsulfonylamino,
 (36) C₁₋₆alkylsulfonylaminomethyl,
 (37) arylsulfonylamino,
 (38) diC₁₋₆alkylaminosulfonyl,
 10 (39) aminosulphonylmethyl,
 (40) C₁₋₆alkylaminosulphonylmethyl, and
 (41) diC₁₋₆alkylaminosulphonylmethyl,
 (42) (CH₂)_mOR¹⁵,
 (43) (CH₂)_mSR¹⁵, provided that R¹⁵ is not hydrogen,
 15 (44) (CH₂)_mSOR¹⁵,
 (45) (CH₂)_mSO₂R¹⁵,
 (46) (CH₂)_mNR¹⁵R¹⁶,
 (47) =O, and



- 20 X¹ and X² are each independently selected from ring nitrogen or
 ring carbon atoms;
 X³ is selected from the group consisting of oxygen, sulfur, -NH-
 or methylene;
 25 Y¹ is oxygen or sulfur;
 n is an integer independently selected at each occurrence from 0
 and 1; and
 m is an integer selected independently at each occurrence from 0
 to 4.

30

INTERNATIONAL SEARCH REPORT

Intern: al Application No
PCT/US 97/13799

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07F7/08 C07D209/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07F C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MURAKAMI, M. ET AL.: "the preparation of (1-(arylimino)alkyl)zinc by the alpha-addition of organozinc to isocyanide" THE JOURNAL OF ORGANIC CHEMISTRY, 1988, pages 4158-4159, XP002043166 see the whole document --- -/--	22,23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

10 October 1997

Date of mailing of the international search report

27. 10. 97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rinkel, L

INTERNATIONAL SEARCH REPORT

Inter national Application No
PCT/US 97/13799

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 89, no. 25, 18 December 1978 Columbus, Ohio, US; abstract no. 215478k, BROOK, A.G. ET AL.: "the syntheses and properties of c-silylimines and their thermal rearrangements to n-silenamines" XP002043170 see abstract & CANADIAN JOURNAL OF CHEMISTRY, vol. 56, no. 17, 1978, pages 2286-2291, ---	22,23
A	WO 95 32197 A (MERCK & CO., INC.) 30 November 1995 cited in the application see the whole document ---	1-21
A	LAROCK, R.C. ET AL.: "synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 113, 1991, pages 6689-6690, XP002043167 cited in the application see the whole document ---	1-21
A	CHEN, C.Y. ET AL.: "synthesis of the 5-HT _{1D} receptor agonist mk-0462 via a Pd-catalyzed coupling reaction" TETRAHEDRON LETTERS, vol. 35, 1994, pages 6981-6984, XP000608320 see the whole document ---	1-21
A	IRITANI, K. ET AL.: "palladium catalyzed reaction of 2-alkynylanilines with allyl chlorides. formation of 3-allylindoles" TETRAHEDRON LETTERS, vol. 29, 1988, pages 1799-1802, XP002043168 see the whole document ---	1-21
P,X	CHEN, C.-Y. ET AL.: "syntheses of indoles via a palladium-catalyzed annulation between iodoanilines and ketones" JOURNAL OF ORGANIC CHEMISTRY, May 1997, pages 2676-2677, XP002043169 see the whole document -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

Initial International Application No

PCT/US 97/13799

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9532197 A	30-11-95	US 5567824 A	22-10-96
		AU 2467195 A	18-12-95
		CA 2190851 A	30-11-95
		EP 0763032 A	19-03-97
		FI 964669 A	22-11-96
		HR 950304 A	31-08-97
